BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Nordic AML Group - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nordic AML Group
X-ORIGINAL-URL:https://www.namlg.org
X-WR-CALDESC:Events for Nordic AML Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240124T153000
DTEND;TZID=Europe/Paris:20240124T163000
DTSTAMP:20260526T095548
CREATED:20240124T110456Z
LAST-MODIFIED:20240124T110456Z
UID:10000007-1706110200-1706113800@www.namlg.org
SUMMARY:NAMLG TWG Meeting - I - 24-01-2024  15:30-16:30 CET
DESCRIPTION:Link and passcode for Teams meeting sent separately. \nAgenda: \n\nUpdate on potential LD-VenEx amendment trial comparing poDEC/LD-VenEx vs. AZA/LD-VenEx (5 min + 10 min discussion).\nNAMLG – platform trial structure concept (5 min): Infrastructure with standing collaboration contracts (clinical trial agreement – CTA) and data processing agreements (DPAs) applicable for all types of trials. This would allow to open trials at one Nordic sponsor site and recruit pts from all Nordic Sites without the requirement to establish new CTAs / DPAs for each trial with individually. Ultimately\, this will establish the NAMLG as partner for pharma-sponsored trials as well as to obtain funding for IIT.\nList/overview of ongoing\, already planned\, and potential future AML trials in the Nordics.\nPresentation and discussion of ongoing and potential novel AML trials\n\nMartin Jädersten – Salvage Treatment + HU (5 min + 5 min discission\nOxcia: Presentation of MAATEO Karonudib + Dauno for RR AML (7 min+ 3 min discussion)\nTrials suggested in previous mail by Bjørn Tore Gjertsen (6 min + 4 min discussion)
URL:https://www.namlg.org/event/namlg-twg-meeting-i-24-01-2024-1530-1630-cet/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240125T160000
DTEND;TZID=Europe/Paris:20240125T170000
DTSTAMP:20260526T095548
CREATED:20240124T102108Z
LAST-MODIFIED:20240124T102108Z
UID:10000006-1706198400-1706202000@www.namlg.org
SUMMARY:Early Response Evaluation by Single-Cell Signaling Profiling in AML
DESCRIPTION:Webinar to be held January 25 at 16:00 \nThis is in Standard Biotools’ (former Fluidigm) Scientist in the Spotlight series. \nMore info and registration on this link. \nHear about: \nInsights into AML response: Discover the initial signaling response to standard induction chemotherapy in a cohort of 32 AML patients. \n  \nPredicting 5-year survival: Learn about the significant predictors of patient 5-year overall survival in this cohort\, specifically the reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation. \n  \nImportance of signaling pathways: See how RNA sequencing and proteomics confirm the mass cytometry data and highlight the potential for this assay to be used in the future of precision oncology.
URL:https://www.namlg.org/event/early-response-evaluation-by-single-cell-signaling-profiling-in-aml/
END:VEVENT
END:VCALENDAR